C.E.S. TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

CONJUGATED ESTROGENS

Доступна з:

BAUSCH HEALTH, CANADA INC.

Код атс:

G03CA57

ІПН (Міжнародна Ім'я):

CONJUGATED ESTROGENS

Дозування:

0.625MG

Фармацевтична форма:

TABLET

Склад:

CONJUGATED ESTROGENS 0.625MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100/1000

Тип рецепту:

Prescription

Терапевтична области:

ESTROGENS

Огляд продуктів:

Active ingredient group (AIG) number: 0106442006; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2020-09-23

Характеристики продукта

PRODUCT MONOGRAPH
PR
C.E.S.

Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL